Key Insights

Highlights

Success Rate

95% trial completion (above average)

Published Results

17 trials with published results (40%)

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 5/100

Termination Rate

2.4%

1 terminated out of 42 trials

Success Rate

95.2%

+8.7% vs benchmark

Late-Stage Pipeline

38%

16 trials in Phase 3/4

Results Transparency

85%

17 of 20 completed with results

Key Signals

17 with results95% success

Data Visualizations

Phase Distribution

36Total
Not Applicable (3)
P 1 (4)
P 2 (13)
P 3 (14)
P 4 (2)

Trial Status

Completed20
Recruiting10
Active Not Recruiting7
Unknown4
Terminated1

Trial Success Rate

95.2%

Benchmark: 86.5%

Based on 20 completed trials

Clinical Trials (42)

Showing 20 of 20 trials
NCT06527404Phase 3Active Not RecruitingPrimary

A Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab in Prurigo Nodularis

NCT06554509Phase 2RecruitingPrimary

Clinical Study of the Efficacy and Safety of SHR-1819 Injection in Adult Patients With Prurigo Nodularis

NCT06342713Phase 1Recruiting

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single- and Multiple-Ascending Doses and Food Effect of BGB-45035 in Healthy Participants and in Adults With Autoimmune Dermatological Diseases

NCT06516965Phase 3Active Not RecruitingPrimary

A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2)

NCT06516952Phase 3RecruitingPrimary

A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1)

NCT06988618RecruitingPrimary

Real-world Experience on Using Nemolizumab in the Treatment of Moderate-to- Severe Prurigo Nodularis in Adults

NCT06366750Phase 2Active Not RecruitingPrimary

A Study of Barzolvolimab in Patients With Prurigo Nodularis

NCT06293053Phase 3RecruitingPrimary

A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥6 Months to <18 Years of Age With Prurigo Nodularis

NCT03816891Phase 2CompletedPrimary

Study to Assess the Efficacy, Safety, and Tolerability of Vixarelimab in Reducing Pruritus in Prurigo Nodularis

NCT05764161Phase 3CompletedPrimary

A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Prurigo Nodularis (PN)

NCT06427122Not ApplicableCompleted

Effect of EMD Protocol for Urge on Dermatology-specific Quality of Life

NCT04204616Phase 3Active Not RecruitingPrimary

A Long-term Study of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)

NCT05991323Active Not RecruitingPrimary

Real-World Effectiveness of Dupilumab in Patients With Prurigo Nodularis: An Observational Study

NCT06087627RecruitingPrimary

A Non-interventional Study to Describe the Dupilumab Long-term Treatment, Safety and Patient Reported Outcomes in Chronic Nodular Prurigo (Prurigo Nodularis) in Clinical Routine

NCT06213831Phase 1CompletedPrimary

A Study to Evaluate the Safety and Tolerability of Maximal Use Ruxolitinib Cream

NCT05928169Recruiting

Determinants of Chronic Inflammatory Skin Disease Trajectories

NCT05061693Phase 2CompletedPrimary

A Study to Evaluate the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis

NCT03497975Phase 2CompletedPrimary

PRISM Study-Pruritus Relief Through Itch Scratch Modulation

NCT06994520Phase 2Active Not Recruiting

Efficacy of Topical Cannabidiol for Eczema

NCT06424470Phase 3Active Not RecruitingPrimary

Study on the Treatment of Prurigo Nodularis With Stapokibart Injection

Scroll to load more

Research Network

Activity Timeline